MedTrace Logo

Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant

NCT00354120 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2023-03-10

No results posted yet for this study

Summary

The purpose of this study is to compare Reduced Intensity Conditioning protocols containing either Thymoglobuline or Alemtuzumab in patients undergoing allogeneic transplant from voluntary unrelated donors.

Conditions

  • Acute Myeloblastic Leukemia
  • Lymphoblastic Leukemia
  • Myelodysplasia
  • Chronic Myeloid Leukemia
  • Myelofibrosis
  • Lympho-proliferative Diseases

Interventions

DRUG

Alentuzumab

Alentuzumab

DRUG

Globulina antilinfocitaria

Globulina antilinfocitaria

Sponsors & Collaborators

  • Gruppo Italiano Trapianto di Midollo Osseo

    lead OTHER

Principal Investigators

  • Alessandro Rambaldi, MD · Divisione di Ematologia - Ospedali Riuniti di Bergamo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00354120 on ClinicalTrials.gov